"N\u00E1kladov\u00E1 efektivita o\u010Dkov\u00E1n\u00ED vakc\u00EDnou Rotarix v \u010Cesk\u00E9 republice"@cs . "Proke\u0161, Michal" . "Tak jako v jin\u00FDch zem\u00EDch i v \u010CR se uva\u017Euje o \u00FAhrad\u011B vakcinace proti rotavirov\u00E9 gastroenteritid\u011B (RV-G) z ve\u0159ejn\u00FDch zdroj\u016F. Proto je nezbytn\u00E9 prov\u00E9st farmakoekonomickou studii, kter\u00E1 by poskytla St\u00E1tn\u00EDmu \u00FAstavu pro kontrolu l\u00E9\u010Div podklady pro zhodnocen\u00ED, zda je \u00FA\u010Deln\u00E9 hradit takov\u00FD vakcina\u010Dn\u00ED program. Tato studie je provedena z perspektivy ve\u0159ejn\u00E9ho zdravotn\u00EDho poji\u0161t\u011Bn\u00ED. P\u0159edpoklady pro z\u00E1kladn\u00ED v\u00FDpo\u010Det jsou: o\u010Dkov\u00E1ny budou v\u0161echny nov\u011B narozen\u00E9 d\u011Bti, vakcinace bude provedena Rotarixem, cena jedn\u00E9 d\u00E1vky vakc\u00EDny bude 1 248,82 K\u010D, diskontace n\u00E1klad\u016F 3%, vakcinace neu\u0161et\u0159\u00ED \u017E\u00E1dn\u00E9 n\u00E1klady na zdravotn\u00ED p\u00E9\u010Di, s kolektivn\u00ED imunitou nebude kalkulov\u00E1no, sn\u00ED\u017Een\u00E1 kvalita \u017Eivota bude po\u010D\u00EDt\u00E1na pouze u nemocn\u00E9ho d\u00EDt\u011Bte. Za t\u011Bchto p\u0159edpoklad\u016F \u010Din\u00ED cena jednoho QALY 1,091 milionu K\u010D, co\u017E je t\u011Bsn\u011B pod horn\u00ED hranic\u00ED hypotetick\u00E9 ochoty platit definovan\u00E9 trojn\u00E1sobkem hrub\u00E9ho dom\u00E1c\u00EDho produktu na obyvatele. Vzhledem k tomu, \u017Ee jsme p\u0159i kalkulaci n\u00E1klady na jedno QALY sp\u00ED\u0161e p\u0159ecenili, m\u016F\u017Eeme p\u0159edpokl\u00E1dat, \u017Ee vakcinace Rotarixem v \u010CR bude pravd\u011Bpodobn\u011B n\u00E1kladov\u011B efektivn\u00ED." . "Like in other countries, the reimbursement of vaccination against rotavirus gastroentwritis (RV-G) from public resources in being considered also in the Czech Republic. For this reason, it is necessary to conduct a pharmacoeconomic study to provide the State Institute fo Drug Control with data needed for the evaluation of efficiency of the RV-G vaccination program.This study has been performed from the perspective of public health funds.Base-care assumptions have been: All newborn cgildren will be vaccinated, vaccination will be performed with Rotarix, the reimbursement of cost of one dose of vaccine wil be 1 248.82 CZK, at a 3% discount rate, no health care cost will be saved by the vaccination, no herd immunity will be calculated and quality of life will be calculated only for sick children. Under these assumption the costs of 1 Quality Adjusted Life Year (QALY) is 1.091 milion CZK, which is just under the willingeness to pay the threshold defined as triple per capita GDP in the Czech Republic. Considering that the cost of QALY in this study is probably overestimated, it is possible to assume that the Rotarix vaccination in the Czech Republic is probably cost effective."@en . . "N\u00E1kladov\u00E1 efektivita o\u010Dkov\u00E1n\u00ED vakc\u00EDnou Rotarix v \u010Cesk\u00E9 republice" . . "Tak jako v jin\u00FDch zem\u00EDch i v \u010CR se uva\u017Euje o \u00FAhrad\u011B vakcinace proti rotavirov\u00E9 gastroenteritid\u011B (RV-G) z ve\u0159ejn\u00FDch zdroj\u016F. Proto je nezbytn\u00E9 prov\u00E9st farmakoekonomickou studii, kter\u00E1 by poskytla St\u00E1tn\u00EDmu \u00FAstavu pro kontrolu l\u00E9\u010Div podklady pro zhodnocen\u00ED, zda je \u00FA\u010Deln\u00E9 hradit takov\u00FD vakcina\u010Dn\u00ED program. Tato studie je provedena z perspektivy ve\u0159ejn\u00E9ho zdravotn\u00EDho poji\u0161t\u011Bn\u00ED. P\u0159edpoklady pro z\u00E1kladn\u00ED v\u00FDpo\u010Det jsou: o\u010Dkov\u00E1ny budou v\u0161echny nov\u011B narozen\u00E9 d\u011Bti, vakcinace bude provedena Rotarixem, cena jedn\u00E9 d\u00E1vky vakc\u00EDny bude 1 248,82 K\u010D, diskontace n\u00E1klad\u016F 3%, vakcinace neu\u0161et\u0159\u00ED \u017E\u00E1dn\u00E9 n\u00E1klady na zdravotn\u00ED p\u00E9\u010Di, s kolektivn\u00ED imunitou nebude kalkulov\u00E1no, sn\u00ED\u017Een\u00E1 kvalita \u017Eivota bude po\u010D\u00EDt\u00E1na pouze u nemocn\u00E9ho d\u00EDt\u011Bte. Za t\u011Bchto p\u0159edpoklad\u016F \u010Din\u00ED cena jednoho QALY 1,091 milionu K\u010D, co\u017E je t\u011Bsn\u011B pod horn\u00ED hranic\u00ED hypotetick\u00E9 ochoty platit definovan\u00E9 trojn\u00E1sobkem hrub\u00E9ho dom\u00E1c\u00EDho produktu na obyvatele. Vzhledem k tomu, \u017Ee jsme p\u0159i kalkulaci n\u00E1klady na jedno QALY sp\u00ED\u0161e p\u0159ecenili, m\u016F\u017Eeme p\u0159edpokl\u00E1dat, \u017Ee vakcinace Rotarixem v \u010CR bude pravd\u011Bpodobn\u011B n\u00E1kladov\u011B efektivn\u00ED."@cs . . "Cost-effectiveness of Rotarix vaccination in the Czech Republic"@en . . "Suchop\u00E1r, Josef" . "cost utility analysis; vaccination; rotavirus infection; Rotarix"@en . "3" . "152839" . "[BEBEBBFC3C10]" . "N\u00E1kladov\u00E1 efektivita o\u010Dkov\u00E1n\u00ED vakc\u00EDnou Rotarix v \u010Cesk\u00E9 republice"@cs . "6"^^ . "Vakcinologie (Vaccinology.)" . "11140" . . "6" . . . . . "Pazdiora, Petr" . . "CZ - \u010Cesk\u00E1 republika" . "RIV/00216208:11140/12:10124027" . "3"^^ . "N\u00E1kladov\u00E1 efektivita o\u010Dkov\u00E1n\u00ED vakc\u00EDnou Rotarix v \u010Cesk\u00E9 republice" . "RIV/00216208:11140/12:10124027!RIV13-MSM-11140___" . "I" . "Cost-effectiveness of Rotarix vaccination in the Czech Republic"@en . "1"^^ . . . . . . "1802-3150" . .